Lost Money on Integra LifeSciences Holdings Corporation Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 21.2% Share Price Drop

Investigation follows the October 2, 2026 disclosure regarding Integra LifeSciences Holdings Corporation; investors who lost money may have claims to recover their losses

LOS ANGELES--(BUSINESS WIRE)--Investors who lost money on Integra LifeSciences Holdings Corporation ("Integra" or the "Company") stock may have claims to recover their losses. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced a securities fraud investigation on behalf of Integra LifeSciences Holdings Corporation (NASDAQ: IART) investors into whether the Company may have violated the federal securities laws. The investigation follows the October 2, 2026 disclosure regarding Integra LifeSciences Holdings Corporation.

Investors who lost money on Integra LifeSciences Holdings Corporation securities can submit their Integra LifeSciences Holdings Corporation loss information to learn about potentially pursuing claims to recover their losses.

Key facts in the Integra LifeSciences Holdings Corporation investigation

• Disclosure date: October 2, 2026
• Stock price decline: $3.41 per share, or 21.2%
• Closing price after the decline: $12.68 on October 2, 2026

What happened?

On October 2, 2026, Integra announced updated full year guidance and preliminary third quarter results. The Company disclosed, among other things, that due to a July flood at its Cincinnati manufacturing facility, “disruption negatively impacted third quarter revenue by approximately $7 million and is expected to negatively impact fourth quarter revenue by approximately $15 million to $20 million.” Integra also slashed its 2026 revenue guidance by approximately $30.5 million at the midpoint. 

On this news, Integra shares fell $3.41 or 21.2%, closing at $12.68 on October 2, 2026, thereby injuring investors.

Then, on October 21, 2026, Integra reported final third quarter results. Among other items, the Company disclosed “the Cincinnati disruption proved more significant than initially expected.” The Company announced it expected fourth quarter revenue of $413 million to $433 million (down 0.5% to 5.2%). The Company further disclosed “more measured expectations for portions of our Tissue Reconstruction business” in part because “growth in Tissue Reconstruction did not materialize as anticipated.”

On this news, Integra’s stock fell $1.49 or 11.18% to close at $11.84 on October 21, 2026, thereby injuring investors further.

"The price of Integra LifeSciences Holdings Corporation shares fell 21.2% following the October 2, 2026 disclosure that Integra had cut its 2026 revenue guidance by approximately $30.5 million at the midpoint and said a July flood at its Cincinnati manufacturing facility reduced third quarter revenue by about $7 million and would reduce fourth quarter revenue by $15 million to $20 million. Investors who suffered losses deserve to know whether they were given complete and accurate information prior to the disclosure, and our investigation seeks to answer that question," said Charles H. Linehan, Partner at Glancy Prongay Wolke & Rotter LLP.

What's the next step?

Glancy is investigating potential claims on behalf of Integra LifeSciences Holdings Corporation investors. Investors who lost money can contact Glancy about the Integra LifeSciences Holdings Corporation investigation, email [e-mail], or call 310-201-9150 (toll-free: 888-773-9224).

Frequently Asked Questions

Who is eligible? Investors who bought Integra LifeSciences Holdings Corporation securities and lost money may have claims, and can contact Glancy to learn whether they are affected by the Integra LifeSciences Holdings Corporation investigation.

What is a securities fraud investigation? In the Integra LifeSciences Holdings Corporation investigation, Glancy is reviewing whether the Company or its executives may have made false or misleading statements to investors in violation of the federal securities laws.

Has a lawsuit been filed? This release announces Glancy's investigation, not a lawsuit. If a securities class action is later filed against Integra LifeSciences Holdings Corporation, investors may have the opportunity to seek appointment as lead plaintiff.

Does it cost anything to contact Glancy or participate in this investigation? Glancy represents Integra LifeSciences Holdings Corporation investors on a contingency fee basis, so investors pay no attorneys' fees out of pocket. Any attorneys' fees and litigation expenses are paid only from a recovery, if one is obtained, and are subject to court approval.

Why work with Glancy on the Integra LifeSciences Holdings Corporation investigation? Glancy Prongay Wolke & Rotter LLP is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Contact Glancy about the Integra LifeSciences Holdings Corporation investigation. Prior results do not guarantee a similar outcome.

Whistleblower notice

Persons with non-public information about Integra LifeSciences Holdings Corporation should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information that leads to a successful SEC enforcement action may receive awards of 10 to 30 percent of the sanctions collected, when those sanctions exceed $1 million. For more information, contact Charles H. Linehan at 310-201-9150 or 888-773-9224, or email [e-mail].

About Glancy Prongay Wolke & Rotter LLP

Glancy was named one of Law360's Securities Groups of the Year and ranked second in total investor recoveries by ISS Securities Class Action Services in 2025.

Glancy's successes have been widely covered by leading news and industry publications, including The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money.

Prior results do not guarantee a similar outcome.

Related links

• Integra LifeSciences Holdings Corporation investigation page, Glancy Prongay Wolke & Rotter LLP
• Integra Q3 Financial Results
• Integra LifeSciences Holdings Corporation SEC filings index, EDGAR
• SEC Whistleblower Program
• Glancy Prongay Wolke & Rotter LLP

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.